Metsera shareholders vote for $10 billion acquisition by Pfizer
The acquisition enhances Pfizer's portfolio, historically increasing stock value post-acquisition.
Public signal · 1-minute delayed
Source-backed market context you can read and share without an account.
The acquisition enhances Pfizer's portfolio, historically increasing stock value post-acquisition.
What happened, with direct paths to the underlying reporting
Metsera shareholders approved Pfizer's $10 billion takeover offer. This deal allows Pfizer to enter the obesity treatment market.
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.